Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00051519 · ClinicalTrials.gov registry record

Screening HIV-Infected Patients for Vaccine Studies

A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
1,000
Enrollment target

NCT00051519: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00051519 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00051519 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
1,000 participants
Enrollment target

Study Summary

This screening study will evaluate potential study volunteers with HIV infection to see if they are suitable candidates for trials of experimental vaccines against HIV (therapeutic), and against other infections (preventive). * Preventive vaccines against other infections. Preventive vaccines prevent a person from getting a disease. Preventive vaccines have been developed for many diseases, including, for example, whooping cough, measles, mumps, influenza, and hepatitis B. Some preventive vaccines may also prevent a disease from taking hold if given immediately after infection, such as vaccines for rabies, smallpox and hepatitis. * Therapeutic vaccines against HIV. Therapeutic vaccines are intended to treat someone who has already been infected, with the goal of controlling the disease or preventing it from causing severe illness. As yet, there are no therapeutic vaccines for any diseases. * Vaccines against other infections. Vaccines to prevent other infections besides HIV may need to be tested separately in people with HIV infection because the immune system works differently when HIV infection is present. HIV-infected patients 18 years of age or older may be eligible for this screening study. Women who are pregnant or breast feeding may not participate. Participants will be screened with the following: * A health history, including questions about sexual activity and drug use; * Physical examination, including blood and urine tests; * HIV testing to confirm HIV infection; * Pregnancy test for premenopausal women; * PPD test for tuberculosis for those who have not been tested in the previous 6 months. Candidates who meet the requirements for investigational vaccine studies will be invited to participate in a study. Those who do not begin a study within 1 month of the screening tests may need to repeat some tests for continued consideration. In addition, some studies require repeated measures of CD4 counts and viral load over a period of a few months.

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2003-01-09
Est. Completion 2007-12-01

What the finished NCT00051519 record still lists

NCT00051519 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT00051519 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00051519 about?

NCT00051519 is a clinical study titled "Screening HIV-Infected Patients for Vaccine Studies". This screening study will evaluate potential study volunteers with HIV infection to see if they are suitable candidates for trials of experimental vaccines against HIV (therapeutic), and against other infections (preventive). * Preventive vaccines against other infections. Preventive vaccines preve...

What is the current status of trial NCT00051519?

This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2003-01-09. Estimated completion is 2007-12-01.

Who is sponsoring clinical trial NCT00051519?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00051519, the US trial registry maintained by the National Library of Medicine. NCT00051519 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.